Acetorphine Stats & Data

Reasoning and evidence for each harm‑reduction addition:

- Legal/scheduling and non‑approval: DrugBank lists Acetorphine as Experimental/Illicit and not approved; isomerdesign’s compiled schedules list it as US CSA Schedule I, UK Class A, and Canada Schedule I. This means any human possession or use carries severe legal risk and there is no medical dosing guidance.

- Extreme potency by class and absence of human dosing: Acetorphine is an oripavine/morphinan derivative closely related to etorphine; there are no validated human dosing data on DrugBank or PubChem. Treat as ultra‑potent; any attempt to extrapolate from veterinary practice is unsafe.

- Depressant combination risks: Authoritative harm‑reduction tables emphasize that opioids combined with benzodiazepines or GHB/GBL are dangerous due to synergistic respiratory depression; large observational datasets also show higher severity for benzo+opioid ED visits. These interactions are therefore listed as Dangerous.

- Gabapentinoids with opioids: Systematic evidence synthesized on NCBI Bookshelf shows increased overdose mortality and hospital/ED utilization when gabapentin or pregabalin are co‑prescribed with opioids; hence marked as Caution.

- MAOIs and certain opioids: TripSit’s interaction guidance and supporting literature flag rare but severe reactions (excitatory and depressive) when opioids are combined with MAOIs; avoid.

- Tramadol with other opioids: TripSit cites elevated seizure risk and additive respiratory depression; listed as Unsafe.

- Overdose response: Community guidelines on opioid overdose care emphasize airway support and naloxone administration, with re‑dosing/monitoring due to naloxone’s shorter action versus many opioids. For ultra‑potent opioids, anticipate multiple naloxone doses and prioritize ventilation until definitive care.

- Duration: No human PK/PD data are available on DrugBank; field experience is veterinary and not transferable to humans; we avoid numeric claims.

- Category correction: Acetorphine is an opioid; it is not a dissociative. DrugBank classifies it structurally as a morphinan; dissociatives act primarily via NMDA antagonism, which is not applicable here.

Operational harm‑reduction guidance:

- Do not attempt any human dosing or self‑experimentation. There is no safe dose window established and fatal toxicity can occur at extremely low exposures compared with common opioids.

- Never combine with other CNS depressants (alcohol, benzos, Z‑drugs, GHB/GBL); these combinations are over‑represented in severe ED outcomes.

- If any exposure is suspected: call emergency services immediately, provide rescue breathing if needed, and administer naloxone promptly; repeat doses may be required. Monitor for renarcotization.

- Gabapentinoids and first‑generation antihistamines substantially increase sedation and respiratory depression; avoid co‑use.

- Avoid MAOIs and tramadol with any potent opioid due to seizure and atypical reactions.

- Legal risk is high across jurisdictions (US/UK/CA scheduling as a narcotic).